Clinical trial PEARLS
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)
| Cancers | |
|---|---|
| Organ | NSCLC |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Merck |
| EudraCT Identifier | 2015-000575-27 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02504372 |
| Inclusion criteria | Adjuvant. ECOG 0 or 1 |
| Last update |